Indications: Alkixen (Crizotinib) 250 mg is prescribed for:

• Treating non-small cell lung cancer (NSCLC) that expresses anaplastic lymphoma kinase (ALK).
• Managing metastatic NSCLC in patients with tumors that are ROS1-positive.

Pharmacology: Crizotinib is a tyrosine kinase inhibitor that works by blocking ALK, ROS1, and c-MET receptor tyrosine kinases. This action disrupts signaling pathways crucial for cancer cell growth and survival, thereby impeding tumor progression.

Dosage and Administration: The recommended dose of Alkixen (Crizotinib) is 250 mg taken orally twice daily, with or without food. Dose adjustments may be necessary depending on individual patient responses and side effects.

Interactions: Crizotinib may interact with other medications, hence patients should inform healthcare providers about all drugs being taken, including prescription, over-the-counter, vitamins, and herbal supplements.

Side Effects: Common adverse effects of Alkixen (Crizotinib) include nausea, vomiting, diarrhea, constipation, fatigue, dizziness, vision disturbances, and abnormal liver function tests. More severe reactions may include interstitial lung disease, hepatotoxicity, and QT prolongation.

Precautions and Warnings: Patients using Alkixen (Crizotinib) should be monitored for signs of interstitial lung disease, hepatotoxicity, and QT prolongation. Regular liver function tests and electrocardiograms may be necessary during treatment. Patients should also be informed about potential vision issues and advised against driving or operating machinery if affected.

Overdose Effects: In the event of overdose, supportive measures are warranted. There is no specific antidote for Crizotinib overdose, and management should focus on addressing symptoms and providing supportive care.